1-8 of 8
Stephanie - Rondeau
Close
Sort by
Journal Articles

Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy

Clinical Trials & Observations
Emanuele Zucca, Stephanie Rondeau, Anna Vanazzi, Bjørn Østenstad, Ulrich J. M. Mey, Daniel Rauch, Björn E. Wahlin, Felicitas Hitz, Micaela Hernberg, Ann-Sofie Johansson, Peter de Nully Brown, Hans Hagberg, Andrés J. M. Ferreri, Andreas Lohri, Urban Novak, Thilo Zander, Hanne Bersvendsen, Mario Bargetzi, Walter Mingrone, Fatime Krasniqi, Stefan Dirnhofer, Stefanie Hayoz, Hanne Hawle, Simona Berardi Vilei, Michele Ghielmini, Eva Kimby
Journal: Blood
Blood (2019) 134 (4): 353–362.
https://doi.org/10.1182/blood-2018-10-879643
Published: 2019
Includes: Supplemental data
Journal Articles

Rituximab Maintenance Treatment for a Maximum of 5 Years in Follicular Lymphoma: Final Results of the Randomized Phase III Trial SAKK 35/03

Christian Taverna, MD, Giovanni Martinelli, MD, Felicitas Hitz, MD, Walter Mingrone, MD, Thomas Pabst, MD PhD, Lidija Cevreska, MD PhD, Auro del Giglio, MD, Anna Vanazzi, MD, Daniele Laszlo, MD, Johann Raats, Daniel Rauch, Daniel Vorobiof, Andreas Lohri, MD, Emanuele Zucca, Celine Rueegsegger, Stephanie - Rondeau, Corinne Rusterholz, Michele Ghielmini
Journal: Blood
Blood (2018) 132 (Supplement 1): 1601.
https://doi.org/10.1182/blood-2018-99-116864
Published: 2018
Journal Articles

Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor–refractory multiple myeloma

Clinical Trials & Observations
Christoph Driessen, Rouven Müller, Urban Novak, Nathan Cantoni, Daniel Betticher, Nicolas Mach, Axel Rüfer, Ulrich Mey, Panagiotis Samaras, Karin Ribi, Lenka Besse, Andrej Besse, Catherine Berset, Stephanie Rondeau, Hanne Hawle, Felicitas Hitz, Thomas Pabst, Thilo Zander
Journal: Blood
Blood (2018) 132 (19): 2097–2100.
https://doi.org/10.1182/blood-2018-05-851170
Published: 2018
Includes: Supplemental data
Journal Articles

Nelfinavir and Lenalidomide/Dexamethasone in Patients with Lenalidomide-Refractory Multiple Myeloma. A Phase I/II Trial — SAKK 39/10

Felicitas - Hitz, MD, Thomas - Pabst, MD, Dagmar - Hess, MD, Marianne Kraus, Lenka Besse, Urban Novak, MD, Katja - Seipel, MD, Stephanie - Rondeau, Silvia - Stüdeli, Simona Berardi, MD, Samaras Panagiotis, MD, Ulrich Mey, MD, Christoph Driessen, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1884.
https://doi.org/10.1182/blood.V130.Suppl_1.1884.1884
Published: 2017
Journal Articles

Rituximab Plus Lenalidomide Versus Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. First Analysis of Survival Endpoints of the Randomized Phase-2 Trial SAKK 35/10

Eva Kimby, MD professor, Stephanie Rondeau, MSc, Anna Vanazzi, MD, Bjorn Ostenstad, MD PhD, Ulrich J.M. Mey, MD, Daniel Rauch, MD, Björn E Wahlin, MD PhD, Felicitas Hitz, MD, Micaela Hernberg, MD, Ann-Sofie Johansson, MD, Peter de Nully Brown, MD PhD, Hans Hagberg, MD PhD, Andres J.M. Ferreri, MD professor, Andreas Lohri, MD professor, Urban Novak, MD, Thilo Zander, MD, Hanne Bersvendsen, MD, Mario Bergetzi, MD, Walter Mingrone, MD, Fatime Krasniqi, MD PhD, Stefan Dirnhofer, MD professor, Hanne Hawle, MD, Simona Berardi, PhD, Michele Ghielmini, MD professor, Emanuele Zucca
Journal: Blood
Blood (2016) 128 (22): 1099.
https://doi.org/10.1182/blood.V128.22.1099.1099
Published: 2016
Journal Articles

The HIV Protease Inhibitor Nelfinavir in Combination with Bortezomib and Dexamethasone (NVd) Has Excellent Activity in Patients with Advanced, Proteasome Inhibitor-Refractory Multiple Myeloma: A Multicenter Phase II Trial (SAKK 39/13)

Christoph Driessen, MD PhD, Rouven Müller, MD, Urban Novak, MD, Nathan Cantoni, MD, Daniel Betticher, Nicolas Mach, Michael Gregor, Panagiotis Samaras, MD, Catherine Berset, Stephanie Rondeau, Hanne Hawle, MD, Felicitas Hitz, MD, Thomas Pabst, MD PhD, Thilo Zander, MD
Journal: Blood
Blood (2016) 128 (22): 487.
https://doi.org/10.1182/blood.V128.22.487.487
Published: 2016
Journal Articles

Rituximab Plus Lenalidomide Improves the Complete Remission Rate in Comparison with Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. Primary Endpoint Analysis of the Randomized Phase-2 Trial SAKK 35/10

Eva Kimby, Giovanni Martinelli, Bjorn Ostenstad, Ulrich JM Mey, Daniel Rauch, Björn E Wahlin, MD PhD, Felicitas Hitz, MD, Micaela Hernberg, Ann-Sofie Johansson, Peter de Nully Brown, Hans Hagberg, Andrés J.M. Ferreri, Andreas Lohri, Urban Novak, Thilo Zander, Hanne Bersvendsen, Mario Bargetzi, Walter Mingrone, Fatime Krasniqi, Stephan Dirnhofer, Hanne Hawle, MD, Simona Berardi, Steffi Demmel, Stephanie Rondeau, Emanuele Zucca, MD
Journal: Blood
Blood (2014) 124 (21): 799.
https://doi.org/10.1182/blood.V124.21.799.799
Published: 2014
Journal Articles

Rituximab Maintenance Treatment For a Maximum Of 5 Years In Follicular Lymphoma: Results Of The Randomized Phase III Trial SAKK 35/03

Christian J. Taverna, MD, Giovanni Martinelli, Felicitas Hitz, Walter Mingrone, Thomas Pabst, MD, Lidija Cevreska, Auro del Giglio, MD, Anna Vanazzi, Daniele Laszlo, Johann Raats, Daniel Rauch, Daniel A. Vorobiof, Andreas Lohri, MD, Emanuele Zucca, MD, Christine Biaggi Rudolf, Stephanie Rondeau, Corinne Rusterholz, Michele Ghielmini, MD
Journal: Blood
Blood (2013) 122 (21): 508.
https://doi.org/10.1182/blood.V122.21.508.508
Published: 2013